Thomas Clozel

Thomas Clozel is the Chief Executive Officer and Co-founder of OWKIN, an artificial intelligence company that focuses on enabling breakthrough medical moments in medicine. In addition to their role at OWKIN, Thomas also holds positions in various companies and organizations, including Université Paris-Saclay, Bioptimus, Cure51, Sofinnova Partners, GRACE, Fragment, Osium AI, and 8400 The Health Network. Thomas also has experience as an investor at Dioxycle. Thomas has a research fellowship in Hematology-oncology from Joan & Sanford I. Weill Medical College of Cornell University and has completed a clinical rotation in the Neurology Department at Icahn School of Medicine at Mount Sinai.